相关实验视频

Updated: Jul 13, 2025

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

胰岛素通过调节2型糖尿病小鼠的肠质细胞功能来抑制炎症反应,通过重塑肠道植物来调节2型糖尿病小鼠的肠质细胞功能

Meng-Ying Li^1,2, Jia-Qi Duan¹, Xiao-Hui Wang¹

¹The Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, The Shaanxi Provincial Key Laboratory of Environmental Health Hazard Assessment and Protection, The Shaanxi Provincial Key Laboratory of Free Radical Biology and Medicine, Department of Health Education and Management, School of Preventive Medicine, Air Force Medical University, West Changle Road No. 169, Xi'an, Shaanxi 710032, China.

|October 16, 2023

概括

胰岛素补充剂通过改变肠道细菌和增加黄油酸来减少2型糖尿病中的结肠炎症. 这调节肠道质细胞,为代谢性疾病提供了潜在的治疗策略.

科学领域:

微生物学微生物学
胃肠病学胃肠病学
免疫学免疫学免疫学

背景情况:

慢性炎症和肠道失调与2型糖尿病 (T2DM) 有关.
食纤维,像胰岛素一样,可以调节肠道微生物群.
肠道质细胞 (EGC) 在肠道炎症中发挥作用.

研究的目的:

为了研究胰岛素对T2DM小鼠结肠炎症的影响.
阐明因林影响肠道微生物群和EGCs的机制.

主要方法:

在T2DM小鼠中注射胰岛素.
分析肠道微生物群组成 (Bacteroidetes/Firmicutes比) 和黄油酸度.
便微生物群移植实验.
使用黄油酸对EGC和炎症通路 (NF-κB) 的体外研究.

主要成果:

胰岛素增加了T2DM小鼠中的Bacteroidetes/Firmicutes比率和黄油酸水平.
便微生物种移植证实了改变肠道菌群的抗炎作用.
黄油酸抑制了NF-κB激活,调节了炎症性细胞因子 (IL-6,TNF-α),并抑制了EGC激活和炎症因子释放.
实验室研究证实了黄油酸的作用.

结论:

胰岛素通过调节肠道微生物群和增加黄油酸来降低T2DM小鼠的结肠炎症.
黄油酸通过影响EGC活动和炎症信号通路来调解这些效应.
胰岛素代表了T2DM相关的肠道炎症的潜在治疗剂.

更多相关视频

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Assessment of Gut Barrier Integrity in Mice Using Fluorescein-Isothiocyanate-Labeled Dextran

Assessment of Gut Barrier Integrity in Mice Using Fluorescein-Isothiocyanate-Labeled Dextran

Published on: November 18, 2022

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...